1. US Food & Drug Administration. FDA approves new HIV treatment for patients with limited treatment options [media release]. 2 July 2020. https://www.fda.gov.
2. US Food & Drug Administration. Rukobia (fostemsavir): US prescribing information. 2020. https://www.accessdata.fda.gov. Accessed 31 July 2020.
3. ViiV Healthcare. ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available [media release]. 10 Jan 2020. https://www.viivhealthcare.com.
4. Bristol-Myers Squibb. Bristol-Myers Squibb completes previously announced sale of its HIV R portfolio to ViiV Healthcare [media release]. 2016. https://www.bms.com.
5. Pancera M, Lai YT, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017;13(10):1115–22.